Clinical Trial Update: Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluates the combination of tocilizumab and atezolizumab in adults with locally advanced or metastatic non-small cell lung cancer refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Actemra (tocilizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Lung Cancer, Nonsmall Cell | Phase 1, Phase 2 | Status: RECRUITING